Novel Cancer Immunotherapies
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
72
NCT05399654
A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
Phase: Phase 1/2
Role: Lead Sponsor
Start: Jun 28, 2022
Completion: May 19, 2026
Loading map...